Business Description
Journey Medical Corp
NAICS : 325412
SIC : 2834
ISIN : US48115J1097
Total Employee Number:
58Compare
Compare
Traded in other countries / regions
DERM.USA Index Membership
Russell 2000Russell 3000 IPO Date
2021-11-12Description
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.07 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 0.83 | |||||
Debt-to-EBITDA | -17.94 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.11 | |||||
Beneish M-Score | -2.33 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.6 | |||||
3-Year EBITDA Growth Rate | 53.1 | |||||
3-Year EPS without NRI Growth Rate | -3.6 | |||||
3-Year FCF Growth Rate | 35.7 | |||||
3-Year Book Growth Rate | 7.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 49.31 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.16 | |||||
9-Day RSI | 58.14 | |||||
14-Day RSI | 57.83 | |||||
3-1 Month Momentum % | 28.03 | |||||
6-1 Month Momentum % | -22.73 | |||||
12-1 Month Momentum % | -12.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.72 | |||||
Quick Ratio | 1.47 | |||||
Cash Ratio | 0.72 | |||||
Days Inventory | 183.16 | |||||
Days Sales Outstanding | 120.12 | |||||
Days Payable | 182.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.2 | |||||
Shareholder Yield % | -5.37 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.44 | |||||
Operating Margin % | -9.8 | |||||
Net Margin % | -14.82 | |||||
EBITDA Margin % | -2.2 | |||||
FCF Margin % | -10.36 | |||||
OCF Margin % | -10.36 | |||||
ROE % | -37.06 | |||||
ROA % | -10.96 | |||||
ROIC % | -16.07 | |||||
3-Year ROIIC % | -525.25 | |||||
ROC (Joel Greenblatt) % | -338.07 | |||||
ROCE % | -12.06 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 56.1 | |||||
PS Ratio | 2.62 | |||||
PB Ratio | 5.87 | |||||
Price-to-Tangible-Book | 41.38 | |||||
EV-to-EBIT | -30.97 | |||||
EV-to-EBITDA | -127.13 | |||||
EV-to-Forward-EBITDA | 16.93 | |||||
EV-to-Revenue | 2.79 | |||||
EV-to-Forward-Revenue | 2.21 | |||||
EV-to-FCF | -26.94 | |||||
Price-to-GF-Value | 1.59 | |||||
| Price-to-Net-Current-Asset-Value | 41.38 | |||||
Earnings Yield (Greenblatt) % | -3.23 | |||||
FCF Yield % | -3.68 |
Journey Medical Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Journey Medical Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 138 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 137 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | In 46 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 45 days | ||
| General meeting for 2026 | 2026-06-24 11:00 | 6.70 (+5.51%) | ||
| A.G.P.’s Annual Virtual Healthcare Conference | 2026-05-20 17:00 | 6.15 (+0.16%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 16:30 | 5.01 (+1.62%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 5.01 (+1.62%) | ||
| Annual report for 2025 | 2026-03-26 | 6.83 (-3.12%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-25 16:30 | 6.91 (+1.17%) |
Show
Entries
Guru Commentaries on NAS:DERM
Press Release
Articles on Journey Medical Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers